Notice of Pre-AIA or AIA Status
The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA .
DETAILED ACTION
Priority
PNG
media_image1.png
16
358
media_image1.png
Greyscale
, is acknowledged.
Status of Claims
Claims 1-20 are currently pending in the application.
Receipt is acknowledged of amendment / response filed on October 22, 2025 and that has been entered.
Information Disclosure Statement
Receipt is acknowledged of Information Disclosure Statement (IDS), filed on 10/22/2025, which has been entered in the file.
Response to Election/Restriction
In response to the restriction requirement Applicants have elected Group I, which includes claims 1-13 and 15-19, drawn to a preparation method for a cannflavin compound of formula I, such as:
PNG
media_image2.png
132
196
media_image2.png
Greyscale
, without traverse, is acknowledged.
Claims 14 and 20 are withdrawn from further consideration pursuant to 37 C.F.R. 1.142 (b) as being drawn to a non-elected subject matter.
Applicants preserve their right to file a divisional on the non-elected subject matter.
Double Patenting
The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970);and, In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).
A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).
Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).
Claims 1-13 and 15-19 are rejected under the judicially created doctrine of obviousness-type double patenting, as being unpatentable over claims 1-13 and 15-20 of co-pending Application No. 18/036,140 (US ‘140). Although the conflicting claims are not identical, they are not patentably distinct from each other because both sets of claims are drawn to the same art recognized subject matter. This is a provisional obviousness-type double patenting rejection, because the conflicting claims have not in fact been patented. The preparation method for a cannflavin compound of formula I taught by co-pending application is similar to instant application, because a reference anticipating one set of claims will render the other obvious and it would have been obvious to one of ordinary skill in the art at the time of the invention was made, since US ‘140 co-pending application teaches the generic method of preparation for a cannflavin compound of formula I, which is similar to the instantly claimed invention.
The subject matter claimed in the instant application is fully disclosed and covered in the US ‘140 co-pending application. Therefore, the disclosure of US ‘140 co-pending application that teaches all the essential elements for the preparation method for a cannflavin compound of formula I [including various reagents and reaction conditions, and the method comprising the steps of :
PNG
media_image3.png
672
582
media_image3.png
Greyscale
, see claim 1 (Currently amended), lines 3-9, page 3, US ‘140] under specific set of reaction conditions, which would easily place Applicants invention in possession of the public before the effective filing date of the claimed invention. The claimed method / process for the preparation of a compound of formula I is so closely related methodically in terms of reagents and reaction conditions as to be analogous method / process of the reference and therefore obvious in the absence of any un-obviousness or unexpected properties. Moreover, any other differences are but obvious with regards to reagents and /or technical modifications, which would be apparent to one skilled in the chemical art that can use similar reagents, reaction steps / conditions, would expect to have the same or essentially the same results. Therefore, in looking at the instantly claimed invention as a whole, the claimed the preparation method for a cannflavin compound of formula I would have been suggested to one skilled in the art and therefore, is obvious, absent evidence to the contrary.
Telephone Inquiry
Any inquiry concerning this communication or earlier communications from the examiner should be directed to Golam Shameem, Ph.D. whose telephone number is (571) 272-0706. The examiner can normally be reached on Monday-Thursday from 7:30 AM - 6:00 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton Brooks, Ph.D. can be reached at (571) 270-7682.
Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://portal.uspto.gov/external/portal. Should you have questions about access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).
Any inquiry of a general nature or relating to the status of this application should be directed to the Group receptionist, whose telephone number is (571) 272-1600.
/GOLAM M SHAMEEM/Primary Examiner, Art Unit 1621